Market Intelligence, Clinical Progress, and High-Purity Reagents for Type 2 Diabetes, Obesity, and MASH Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GCGR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GCGR ECD-Fc Fusion Protein (Human/Cyno/Mouse orthologs). HEK293 expressed (Native Glycosylation). High purity (>95%). Endotoxin <1 EU/µg. Sequence Verified. | View GCGR Products |
| Gene Delivery | GCGR Full-Length ORF Lentivirus Premade Particles. For stable cell line generation. Preserves native 7-TM GPCR conformation. Sequence Verified. | View GCGR Products |
| Benchmark Ab | Anti-GCGR Neutralizing Antibody (Sequence-matched to clinical benchmark clone, including REMD-477). Recombinant positive control. Sequence Verified. | View GCGR Products |
| Validator | GCGR siRNA Set (3 target-specific + 1 scramble). For knockdown validation and specificity control. Sequence Verified. | View GCGR Products |
| Related Target 1 | GLP1R. Synergistic co-agonist partner for obesity and type 2 diabetes combination therapy. | View GLP1R Products |
| Related Target 2 | GIPR. Triple-agonist axis partner (GCGR/GLP-1R/GIPR) for next-generation metabolic drugs. | View GIPR Products |
| Related Target 3 | GLP2R. Class B GPCR subfamily member; critical for selectivity counter-screening. | View GLP2R Products |
Critical Assay Requirements
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species (Cyno/Mouse) Evaluation | Human/Cyno/Mouse GCGR ECD-Fc proteins and lentivirus available; sequence-verified ORFs for preclinical translation. |
| GPCR Conformational Integrity | Full-length lentivirus particles (>90% purity, Endotoxin <5 EU/ml) for stable cell line generation; maintains native glycosylation and 7-TM structure required for functional assays. |
| Subfamily Selectivity (vs GLP-1R/GIPR) | Homolog panel (GLP1R, GIPR, GLP2R) proteins strictly verified by mass spec for off-target binding assays; sequence identity mapped. |
| Functional Validation (cAMP/Calcium) | Cell-based assays using GCGR-lentivirus transduced lines; Gs-coupled cAMP modulation and calcium flux detection. |
| Lack of Controls | Clinical Benchmark Antibodies (including REMD-477 biosimilar) included for assay calibration and validation. |
| False Positives / Specificity | Validated siRNA included for specificity checks and target engagement confirmation. |
Live GCGR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GCGR therapeutics has shifted decisively from first-generation antagonist-based glucose control (e.g., LY2409021, MK-0893) to unimolecular co-agonism. Early GCGR antagonists faced safety liabilities such as hepatotoxicity and alpha-cell hyperplasia, leading to clinical discontinuations. The current focus is on dual and triple agonists combining GCGR, GLP-1R, and GIPR activity, aiming to maximize energy expenditure and hepatic fat clearance while tightly controlling hyperglycemic risk. Key programs include Eli Lilly's retatrutide (GIP/GLP-1/GCGR triple agonist) and Boehringer Ingelheim's survodutide (GCGR/GLP-1R dual agonist), both advancing through Phase 3. Future R&D will target refined signaling bias, liver-targeted delivery, and long-acting subcutaneous formulations to balance metabolic efficacy and safety.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody Antagonist | REMD Biotherapeutics (REMD-477) | Diabetes | Full-length GPCR cell lines required for functional blocking assays |
| Dual Agonist (GCGR/GLP-1R) | Boehringer Ingelheim, Altimmune | Obesity, MASH | Receptor activation ratio assay (need lentivirus for cell lines) |
| Triple Agonist (GIP/GLP-1/GCGR) | Eli Lilly | Obesity, MASH | Receptor activation ratio assay (need lentivirus for cell lines) |
| Bispecific Antibody | Various Biotech | T2D | Heterodimer validation (need cross-reactive Abs and GLP1R/GCGR cells) |
| Small Molecule | Pfizer, Structure Therapeutics | Metabolic Syndrome | Selectivity assay (need structural conformation integrity) |